Matthew Foy serves as Executive at Decibel Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Matthew Foy has executed 4 insider transactions totaling $2.7M, demonstrating a bullish approach to their equity position. Their most recent transaction on Feb 17, 2021 involved purchasing 150,000 shares valued at $2.7M.
Matthew Foy currently holds 1,183,663 shares of Decibel Therapeutics, Inc. (DBTX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Matthew Foy has been a net buyer of DBTX stock. They have purchased $2.7M and sold $0 worth of shares.
Matthew Foy's most recent insider trade was on Feb 17, 2021, when they purchased 150,000 shares at $18.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Feb 17, 2021 | DBTX | $0 | Conversion | 247,324 | $N/A | Discretionary |
| Feb 17, 2021 | DBTX | $0 | Conversion | 458,487 | $N/A | Discretionary |